Research Studies
Interstitial Lung Disease Program (ILD)
Select the Research Study to view.
- FG-3019-049 (Fibrogen): A Phase 2a, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects with Idiopathic Pulmonary Fibrosis
Status: Active - Enrolling.
- PANTHER (NHLBI / Duke): Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in People With Idiopathic Pulmonary Fibrosis
Status: Active - Enrolling.
- PIPF-012 (InterMune): An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Active - Enrolling.
- PIPF-016 (Intermune): A Randomized, Double Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Status: Active - Enrolling.
